ARID1A alterations and their clinical significance in cholangiocarcinoma
Open Access
Abstract
Background: ARID1A is a member of the SWI/SNF chromatin remodeling complex. It functions as a tumor suppressor and several therapeutic targets in ARID1A-mutated cancers are currently under development, including EZH2. A synthetic lethal relationship between ARID1A and EZH2 has been revealed in several tumor entities. Although genomic alterations of ARID1A have been described in various cancers, no study has examined correlations between ARID1A gene mutation and protein expression with clinicopathologic parameters and prognosis, particularly in liver fluke-related cholangiocarcinoma (Ov-CCA). Here, we investigated the clinical significance of ARID1A mutations and protein expression in CCA tissues and determined whether there is a correlation with EZH2 protein expression. Methods: We evaluated ARID1A and EZH2 immunoreactivity using immunohistochemistry in 98 Ov-CCA with a wide range of clinicopathological features. Somatic mutations of ARID1A were analyzed using the ICGC sequencing data in 489 of Ov and non Ov-CCA and assessed prognostic values. Results: While detecting a loss or reduction of ARID1A expression in 54 cases (55%) in Ov-CCA, ARID1A expression was associated with ARID1A mutations (p < 0.001, adjusted p-value < 0.001). We observed that 12 of 13 tumors (92%) with loss of ARID1A expression had truncating mutations. There were nine of 13 tumors (69%) with loss of ARID1A expression and 25 of 41 tumors (61%) with low ARID1A expression exhibited distant metastasis (p = 0.028, adjusted p-value = 0.168). ARID1A was predominantly mutated in Ov-CCA compared to non Ov-CCA (24% and 14% in Ov-CCA and non Ov-CCA, respectively, p = 0.027). There were 36 of 72 (50%) and 52 of 79 (66%) tumors with ARID1A mutation showed tumor stage IV and T3/T4, respectively. The significant mutual exclusivity and co-occurrence between ARID1A and TP53/KRAS mutations were not found in ICGC cohort. In addition, high EZH2 expression, a potential synthetic lethal target in ARID1A-mutated tumors, was detected in 49 of 98 Ov-CCA (50%). Importantly, neither ARID1A expression nor ARID1A mutations correlated with EZH2 expression in this cohort. Conclusion: We found that ARID1A inactivation, by somatic mutation or by loss of expression, frequently occurs in Ov-CCA. Reduction of ARID1A expression and/or somatic mutation was shown to be associated with CCA progression. These findings suggest that ARID1A may serve as a prognostic biomarker, and thus may be a promising therapeutic target for CCA.Keywords
Funding Information
- the young researcher development project of khon kaen university
- Centre for Research and Development of Medical Diagnostic Laboratories
- Faculty of Associated Medical Sciences, Khon Kaen University
- Thailand Research Fund (MRG6280073)
This publication has 47 references indexed in Scilit:
- Prognostic role of ARID1A negative expression in gastric cancerScientific Reports, 2019
- High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective studyBMC Cancer, 2019
- EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancersGynecologic Oncology Research and Practice, 2017
- Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)Nature Reviews Gastroenterology & Hepatology, 2016
- Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancersNature Medicine, 2015
- A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancerAnnals of Oncology, 2015
- Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic ImplicationsPLOS ONE, 2014
- Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancersNature Genetics, 2013
- A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in EuropeAnnals of Oncology, 2013
- ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250aProceedings of the National Academy of Sciences, 2008